Karilyn Larkin, MD
Hematology · Columbus, OHNPI 1376861187
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,020 of the $10,270 with a category attached, or 87.8%. Astellas Pharma US Inc accounts for 77.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $7,962 and has fallen 99.5% since, to $38 in 2022. That places this record below the midpoint for hematology clinicians in OH, where the typical reported total is $9,915.
Across 7 payments — averaging $1467.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$8K
- Gilead$2K
- Pfizer$38
Across 11 payments — averaging $9314.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- National Marrow Donor Program$79K
- Gilead$24K
What the payments were for
- Consulting fees$9,02088%
- Travel & lodging$1,10111%
- Food & beverage$1491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $7,962 |
| Gilead | 1 | $2,270 |
| Pfizer | 1 | $38 |
How this compares
$10,270 in reported general payments places this provider in the 50th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 35 | $640,936 |
| IclusigPonatinib Hcl | 11 | $237,992 |
| JakafiRuxolitinib Phosphate | 14 | $213,630 |
| VenclextaVenetoclax | 23 | $129,087 |
| SorafenibSorafenib Tosylate | 11 | $11,621 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.